Nebivolol Arx (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also enhances nitric‑oxide release from the endothelium, causing vasodilation. The combined effect lowers systemic blood pressure and eases the workload on the heart.

The appropriate dose of Nebivolol Arx is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any co‑existing health issues. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nebivolol Arx product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly β1‑selective blocker with additional nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects and better tolerability compared with non‑selective beta blockers. Its unique vasodilatory property may offer advantages in patients who experience fatigue or cold extremities on other agents.

Store Nebivolol Arx at room temperature, below 25 °C, in the original blister or bottle. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Nebivolol Arx is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not split or crush the tablet unless instructed.

Serious adverse events include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling, or difficulty breathing.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block, uncompensated heart failure, or severe asthma/COPD where β‑blockade could precipitate bronchospasm.